CAS: 122647-32-9; N-(4-(4-(Ethyl(Heptyl)Amino)-1-Hydroxybutyl)Phenyl)Methanesulfonamide Hemifumarate

该化合物是一种化学化合物,其结构复杂,包括甲烷硫氨基混合物和丁二亚基亚酸成分.该化合物通常具有与全氟辛烷磺酸和氨基酸相关的特性,有可能影响其溶解性和再活动.由于乙基乙基氨基氨组的存在,该化合物可能拥有生物活动,这可以增强脂性,促进膜的渗透性.丁二烯部分表明生物化学途径中存在相互作用的可能性,可能在不同生物系统中作为木质或模具.盐形式表明,该化合物在某些溶剂中可能比中性对应剂更加稳定或溶解.

结构式图片

欧盟法规

C&L通报

上下游产品

4-(ethylamino)butanoic acid hydr°Chloride ibutilide (2E)-but-2-enedioic acid

合成工艺路线路线简述

    4-(Ethylamino)Butanoic Acid Hydrochloride置于aluminum (III) Chloride,Lithium Aluminium Tetrahydride,氯化亚砜,Sodium Hydroxide体系中,用 四氢呋喃,二硫化碳,乙醇,二氯甲烷,水 用作溶剂,化学反应 25.0H,反应生成伊布利特半富马酸盐
    参考文献:A Novel Synthesis Of Ibutilide Fumarate
    标题:A Novel Synthesis Of Ibutilide Fumarate
    摘要:一种新颖的伊布利特富马酸盐(消旋体)合成协议已从2-吡咯烷酮实现,总体产率为15%.核心结构在一步骤中基于friedel-Crafts酰基化反应构建,使用含有氨基盐酸盐的酰氯.
    Doi:10.2174/157017811796064412

    专利信息


    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-6693122-B2
    优先权日:1999-05-12
    标题:Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
    发明人:GARVEY DAVID S; SAENZ DE TEJADA INIGO
    权利人:NITROMED INC
    摘要:The present invention describes novel nitrosated and/or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and/or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

    专利号:US-2014315720-A1
    优先权日:2012-10-24
    标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
    发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
    权利人:CELANESE ACETATE LLC
    摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

    专利号:CN-108569987-A
    优先权日:2017-03-10
    标题:A kind of synthesis technology of intermediate
    湖北天舒药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.tianshupharm.com
    企业联系电话:0710-4280293;18771522777刘经理👤
    📞湖北天舒药业有限公司 ⚠️参考联系方式
    联系人:刘经理
    电话:0710-4280293;18771522777刘经理
    手机:18771522777刘经理
    传真:0710-4280291
    邮箱:1192828343@qq.com
    通信地址: 宜城市精细化工产业园雷河南路
    邮编:
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:宜城市精细化工产业园雷河南路
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    南京旋光科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.robiot.com
    企业联系电话:025-84391590,83322518👤
    📞南京旋光科技有限公司 ⚠️参考联系方式
    联系人:祝轶
    电话:025-84391590,83322518

    传真:025-84391596
    邮箱:sales@robiot.com
    通信地址: 南京市鼓楼区新模范马路5号
    邮编: 210008
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:南京市鼓楼区新模范马路5号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    湖北志化医药化学有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zhihuachem.com
    企业联系电话:13797666691👤
    📞湖北志化医药化学有限公司 ⚠️参考联系方式
    联系人:杨经理
    电话:13797666691
    手机:13797666691
    传真:0710-4280293
    邮箱:zhsale@zhihuachem.com
    通信地址: 湖北宜城市流水镇原邓林农场三分场境内
    邮编: 441419
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:湖北宜城市流水镇原邓林农场三分场境内
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. J Am Board Fam Med. 2011 Jan-Feb;24(1):86-92. doi: 10.3122/jabfm.2011.01.080096. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. doi: 10.3122/jabfm.2011.01.080096. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review.

    合成参考文献


    参考文献:10.1007/bf02253566|10.1159/000025393
    摘要:Lai L, Su M, Tseng Y, Lien W. Sensitivity of the Slow Component of the Delayed Rectifier Potassium Current (IKs) to Potassium Channel Blockers: Implications for Clinical Reverse Use-Dependent Effects. Journal of Biomedical Science. 1999 Jul 16;6(4):251–9. doi: 10.1159/000025393.
    参考文献:10.1007/s11936-001-0028-3
    摘要:Balaji S. Postoperative cardiac arrhythmias in children. Current Treatment Options in Cardiovascular Medicine. 2001 Oct;3(5):385–92. doi: 10.1007/s11936-001-0028-3.
    参考文献:10.1007/s00380-003-0750-8
    摘要:Hiramatsu M, Wu LM, Hirano Y, Kawano S, Furukawa T, Hiraoka M. Block of HERG current expressed in HEK293 cells by the Na+-channel blocker cibenzoline. Heart Vessels. 2004 May;19(3):137–43. doi: 10.1007/s00380-003-0750-8.
    参考文献:10.1007/s00508-008-0940-6
    摘要:Altmann D, Eggmann U, Ammann P. [Drug induced QT prolongation]. Wien Klin Wochenschr. 2008;120(5-6):128–35. doi: 10.1007/s00508-008-0940-6.
    参考文献:10.2165/00003495-200868050-00004
    摘要:Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs. 2008;68(5):607–30. doi: 10.2165/00003495-200868050-00004.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知